<SEC-DOCUMENT>0000950170-24-059668.txt : 20240514
<SEC-HEADER>0000950170-24-059668.hdr.sgml : 20240514
<ACCEPTANCE-DATETIME>20240514163441
ACCESSION NUMBER:		0000950170-24-059668
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240511
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240514
DATE AS OF CHANGE:		20240514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viracta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001061027
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943295878
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51531
		FILM NUMBER:		24945042

	BUSINESS ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007
		BUSINESS PHONE:		858-400-8470

	MAIL ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOSAIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUNESIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980501
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>virx-20240511.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-14T16:33:08.0924+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:virx="http://viracta.com/20240511" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_b7edf96c-794a-42a4-84dd-2c7fedebb45b" name="dei:EntityCentralIndexKey" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da">0001061027</ix:nonNumeric><ix:nonNumeric id="F_267b1bc7-c8c7-4182-993a-ae035f4151c7" name="dei:AmendmentFlag" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da">false</ix:nonNumeric><ix:nonNumeric id="F_3bbcc399-9f38-4064-a2ad-82842024fb72" name="dei:EntityRegistrantName" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da">Viracta Therapeutics, Inc.</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="virx-20240511.xsd"/></ix:references><ix:resources><xbrli:context id="C_07c6a872-44b2-4f1f-8947-e6528df029da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001061027</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-11</xbrli:startDate><xbrli:endDate>2024-05-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56dac0f8-c68b-4d0a-b43d-2cc3654709f4" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_7c3dad9d-83d8-4777-a997-d82e8ec539ba" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">May 11, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3bbcc399-9f38-4064-a2ad-82842024fb72;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">VIRACTA THERAPEUTICS, INC.</span></span></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_999ddabf-d760-42f6-853e-964c2998b0c0" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f52fc544-3724-4e39-b4da-9ddadf28e5ca" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">000-51531</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_82a76906-381e-44f6-b5a6-a18d73d0d98a" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94-3295878</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d32c7eed-e02d-4c06-a0b4-c229cf36794a" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2533 S. Coast Hwy. 101, Suite 210</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_38149988-987f-45a4-923c-3ae7a06214c8" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cardiff</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_12f6da04-b136-4be5-94f3-1845c8df1159" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_44ca4d6e-b5d1-45e4-bb7b-1116417169c7" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92007</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_fbdf5322-9b69-4d88-8455-5a6dd7236432" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_e105fc6c-3f75-4e56-b96e-03c2fd159cab" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">400-8470</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_976b2a25-fb6c-450d-b313-06b3a1953286" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_faa07df1-dca3-49b9-a2ba-646d59860885" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd3125fe-6add-4a99-8f14-ebb810133a23" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee7bb1dc-56cd-4cb5-8801-def081590c9b" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5fbc1138-b951-46c7-a0ab-bca915b4be4b" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock,  par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dd9a21b9-3718-4fa5-9193-0154a4800fcb" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">VIRX</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e84909f1-1aec-49c5-bb0b-26c015cfc4db" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_55d3573e-4ef3-4d5a-9692-2298c70bc72a" contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Appointment of Chief Financial Officer</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 11, 2024, the Board of Directors (&#8220;Board&#8221;) of Viracta Therapeutics, Inc. (the &#8220;Company&#8221;) appointed Michael Faerm to serve as the Company&#8217;s Chief Financial Officer, effective May 13, 2024 (the &#8220;effective date&#8221;). In connection with Mr. Faerm&#8217;s appointment as Chief Financial Officer, Mr. Faerm will also serve as the Company&#8217;s principal financial officer and principal accounting officer, and Melody Burcar, the Company&#8217;s Senior Vice President of Finance, will no longer serve as the Company&#8217;s interim principal financial officer and interim principal accounting officer. Ms. Burcar will continue to serve as the Company&#8217;s Senior Vice President of Finance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Faerm most recently served in a consulting role as Interim Chief Financial Officer of Harpoon Therapeutics, Inc., a publicly-traded immunotherapy company, from October 2023 to March 2024. From April 2021 to March 2023, Mr. Faerm served as Chief Financial Officer of Artiva Biotherapeutics, Inc., a natural killer (NK) cell-based therapy company. From 2019 to 2021, Mr. Faerm served as a consulting and interim Chief Financial Officer and Chief Business Officer to various biopharmaceutical companies through his consulting firm, MEF Consulting LLC. From 2015 to 2018, Mr. Faerm served as Chief Business Officer of Innoviva, Inc. (formerly Theravance, Inc.), a publicly-traded biopharmaceutical company. Prior to Innoviva, Mr. Faerm served as a senior pharmaceuticals equity research analyst at Wells Fargo Securities and at Credit Suisse. Mr. Faerm holds a M.B.A. from Harvard Business School, a M.S. in civil engineering from Stanford University and a B.S. in civil engineering from Columbia University.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chief Financial Officer Compensation Arrangements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also on May 11, 2024, the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;) approved, and the Company entered into, an Executive Employment Agreement with Mr. Faerm (the &#8220;employment agreement&#8221;), to be effective on the effective date. Mr. Faerm&#8217;s employment under the employment agreement is at will and may be terminated at any time by the Company or by Mr. Faerm. Pursuant to the employment agreement, Mr. Faerm will receive an annual base salary of $480,000 and a discretionary annual target bonus of up to forty percent (40%) of his annual base salary (the &#8220;target bonus&#8221;), based on the achievement of performance objectives to be determined by the Board or an authorized committee thereof. Under the employment agreement, for the Company&#8217;s 2024 fiscal year, any bonus payable to Mr. Faerm will be prorated for the portion of the year that Mr. Faerm is employed by the Company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the employment agreement, Mr. Faerm will also receive an option to purchase 500,000 shares of the Company&#8217;s common stock (the &#8220;initial option&#8221;) with an exercise price per share equal to the per share fair market value of the Company&#8217;s common stock on the date of grant. The initial option will vest with respect to twenty-five percent (25%) of the total number of shares granted on the first anniversary of the effective date, and with respect to one-forty-eighth (1/48) of the total number of shares granted on the last day of each one-month period of Mr. Faerm&#8217;s service to the Company thereafter. Also pursuant to the employment agreement, if, on or before December 31, 2024, the Company completes a financing that extends the Company&#8217;s runway through the end of fiscal year 2025, as determined by the Board, Mr. Faerm will receive an additional option</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to purchase 340,000 shares of the Company&#8217;s common stock (the &#8220;financing option&#8221;). The financing option will have an exercise price per share equal to the per share fair market value of the Company&#8217;s common stock on the date of grant and will vest according to the same vesting schedule as the initial option. The initial option and the financing option will each be granted pursuant and subject to the terms and conditions of the Company&#8217;s equity incentive plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company terminates Mr. Faerm&#8217;s employment other than for &#8220;cause,&#8221; death or &#8220;disability,&#8221; or Mr. Faerm resigns for &#8220;good reason&#8221; outside the period beginning three (3) months prior to a &#8220;change in control&#8221; (as all such terms are defined in the employment agreement) and ending twelve (12) months following a change in control (such period, the &#8220;change in control period&#8221;), Mr. Faerm will be entitled to: (i) continued payment of his base salary, as in effect immediately prior to his termination date, for a period of twelve (12) months; and (ii) reimbursement by the Company for the cost of continuation of health coverage for Mr. Faerm and his eligible dependents pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;), for up to twelve (12) months.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company terminates Mr. Faerm&#8217;s employment other than for cause, death or disability, or Mr. Faerm resigns for good reason during the change in control period, Mr. Faerm will be entitled to: (i) a lump sum payment equal to twelve (12) months of his base salary as in effect immediately prior to Mr. Faerm&#8217;s termination date; (ii) a lump sum payment equal to one hundred percent (100%) of Mr. Faerm&#8217;s target bonus for the year in which such termination occurs; (iii) reimbursement by the Company for the cost of premiums for continued coverage under COBRA for up to twelve (12) months; and (iv) acceleration of the unvested portion of any stock options or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other equity awards held by Mr. Faerm immediately prior to termination (with any performance-based vesting assumed at target performance).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a change in control occurs while Mr. Faerm remains employed by the Company, fifty percent (50%) of the unvested portion of any stock options or other equity awards held by Mr. Faerm that remain outstanding as of immediately prior to such change in control shall immediately vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing severance benefits are conditioned upon Mr. Faerm signing and not revoking a release of claims within 60 days following his employment termination date and his continuing compliance with the terms of a confidentiality and information agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of the payments provided for under the employment agreement or otherwise payable to Mr. Faerm would constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Internal Revenue Code and would be subject to the related excise tax under Section 4999 of the Internal Revenue Code, then he will be entitled to receive either full payment of benefits or such lesser amount that would result in no portion of the benefits being subject to the excise tax, whichever results in the greater amount of after tax benefits to him.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary of Mr. Faerm&#8217;s executive employment agreement set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the executive employment agreement, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company has entered into its standard form of indemnification agreement with Mr. Faerm. The form indemnification agreement was filed with the Securities and Exchange Commission on December 23, 2004, as Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 and is incorporated herein by reference. Mr. Faerm has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, nor are any such transactions currently proposed. There is no arrangement or understanding between Mr. Faerm or any other person pursuant to which Mr. Faerm was selected as an officer. There are no family relationships between Mr. Faerm and any of the Company&#8217;s directors or executive officers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Increase in Shares Reserved Under Inducement Plan</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 11, 2024, in connection with the appointment of Mr. Faerm as the Chief Financial Officer of the Company and the approval of his employment agreement, the Board also approved increasing the number of shares of common stock reserved under the Company&#8217;s 2021 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;) by 1,200,000 shares, to a new total of 3,575,000 shares of common stock. As previously disclosed, the Board adopted the Inducement Plan without stockholder approval pursuant to Rule 5635(c)(4) and Rule 5635(c)(3) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals&#8217; bona fide period of non-employment with the Company), as an inducement material to the individuals&#8217; entry into employment with the Company or in connection with a merger or acquisition, to the extent permitted by Rule 5635(c)(3) of the NASDAQ Listing Rules.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01. Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 14, 2024, the Company issued a press release announcing the appointment of Mr. Faerm as the Company&#8217;s Chief Financial Officer. A copy of the press release is furnished herewith as Exhibit 99.1.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01. Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(d) Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.14%;"/>
    <td style="width:4.84%;"/>
    <td style="width:89.02%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="virx-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement by and between the Company and Michael Faerm, dated as of May 11, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="virx-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release, dated May 14, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"/>
    <td style="width:44%;"/>
    <td style="width:4%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Viracta Therapeutics, Inc</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 14, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mark Rothera</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark Rothera<br/>President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>virx-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;padding-left:0.92in;width:6.66in;padding-right:0.92in;"><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:117.6pt;text-indent:30pt;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.0743055555555554in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT</font></p><p style="margin-left:24pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08124999999999999in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Employment Agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and between Viracta Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Michael E. Faerm (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is effective as of May 13, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.5798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.112034876715629%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__duties_and_scope_of_employment_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Duties and Scope of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__positions_and_duties__executive_will"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Positions and Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Executive will serve as Chief Financial Officer of the Company. Executive will render such business and professional services in the performance of Executive&#x2019;s duties, consistent with Executive&#x2019;s position within the Company, as will reasonably be assigned to Executive by the President &amp; CEO or the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). For clarification, the Executive may serve in his position from a hybrid location, in accordance with Section (d). The period of Executive&#x2019;s employment from the Effective Date </font><font id="xb__obligations___during_the_employment_"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is referred to herein as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employment Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. During the Employment Term, Executive shall perform Executive&#x2019;s duties faithfully and to the best of Executive&#x2019;s ability and shall devote substantially all of Executive&#x2019;s business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation, or consulting activity for any direct or indirect remuneration which would conflict or interfere with the performance of such services without the prior approval of the Board. Notwithstanding the foregoing, Executive shall have the right, with the prior written consent of the Board, to serve as a member of the board of directors or comparable governing bodies (including any board committees) of one for-profit business.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__at_will_employment__the_parties_agre"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">At-Will Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The parties agree that Executive&#x2019;s employment with the Company will be &#x201c;at-will&#x201d; employment and may be terminated at any time with or without cause or notice. Executive understands and agrees that neither Executive&#x2019;s job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive&#x2019;s employment with the Company. However, as described in this Agreement, Executive may be entitled to severance benefits depending on the circumstances of Executive&#x2019;s termination of employment with the Company.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__work_location__executive_s_primary_w"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Work Location</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Executive&#x2019;s primary work location will be the Company office in Cardiff, California. Notwithstanding the foregoing, to the extent that it does not interfere with the performance of Executive&#x2019;s duties, Executive may work from his home office in California; provided that the Company may in its discretion determine to set a minimum requirement for Executive to work from the Company&#x2019;s headquarters. Executive shall allocate sufficient time working in person at the Company&#x2019;s headquarters in Cardiff, California, while incorporating considerations such as travel restrictions, social distancing measures, virtual conferences and internet-based meetings against business impact and timely execution on deliverables. </font></div></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.5798611111111112in;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.112034876715629%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__compensation_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__base_compensation__during_the_employ"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. During the Employment Term, the Company will pay Executive an annual salary of $480,000, less applicable withholdings, as compensation for Executive&#x2019;s services (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which will be paid periodically in accordance with the Company&#x2019;s normal payroll practice. Executive&#x2019;s salary will be subject to review and adjustments may be made in the Company&#x2019;s sole discretion.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__employee_benefits__during_the_employ"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. During the Employment Term, Executive will be entitled to participate in the employee benefit plans and programs currently and hereafter maintained by the Company of general applicability to other senior executives of the Company, including, without limitation, the Company&#x2019;s 401(k) retirement plan, employee stock purchase plan, group medical, dental, vision, disability, life insurance, and flexible-spending account plans, if any, pursuant to the terms and conditions of such plans. The Company reserves the </font><font id="xc__paid_time_off_vacation__during_the_e"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">right to cancel or change the benefit plans and programs it offers to its employees at any time.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Paid Time Off/Vacation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. During the Employment Term, Executive will be entitled to accrue paid time-off/vacation in accordance with the Company&#x2019;s paid-time off policies. Accrued and unused vacation will carry over from year to year, as required by applicable California law, up to a cap of no more than 30 days.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__target_bonus__executive_will_be_elig"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Target Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Executive will be eligible to receive an annual bonus of up to forty percent (40%) of the Executive&#x2019;s Base Salary (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Target Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), less applicable withholdings, upon achievement of performance objectives to be determined in good faith by the Board or an authorized committee thereof (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in its sole discretion. The Target Bonus, or any portion thereof, will be paid as soon as practicable after the Board determines such bonus has been earned. In order to earn any bonus, Executive must be employed by the Company on the date the bonus is paid. Executive will not be eligible for a bonus if Executive&#x2019;s employment with the Company terminates prior to the payment date, regardless of whether Executive or the Company initiates the termination, and independent of whether the termination is with or without cause. For 2024, the Target Bonus will be prorated for the </font><font id="x__equity_"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">portion of the year that the Executive was employed by the Company.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.5798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.112034876715629%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="xa__as_soon_as_practicable_following_the"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xb__executive_will_be_eligible_to_receiv"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Initial Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. As soon as practicable following the Effective Date and subject to approval by the Board or the Compensation Committee of the Board, as a material inducement to Executive&#x2019;s acceptance of employment with the Company, Executive will be granted a stock option to purchase 500,000 shares of the Company&#x2019;s common stock, with an exercise price per share equal to the per share fair market value of the Company&#x2019;s common stock on the date of grant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Initial Option will be granted pursuant to the Company&#x2019;s equity incentive plans (the plan under which such Initial Option is granted is referred to herein as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Initial Option will vest with respect to twenty-five percent (25%) of the total number of shares of the Company&#x2019;s common stock subject to the Initial Option on the first anniversary of the Effective Date, and with respect to one-forty-eighth (1/48) of the total number of shares of the Company's common stock subject to the Initial Option on the last day of each one-month period of Executive&#x2019;s service to the Company </font></div></div><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.3298611111111111in;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">thereafter. The Initial Option will be subject to the terms and conditions of the Plan and any form of stock option agreement issued thereunder.</font></div></div><p style="margin-left:95.95pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.08124999999999999in;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financing Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. As a further material inducement to Executive&#x2019;s acceptance of employment with the Company, subject to approval by the Board or the Compensation Committee of the Board, if, on or before December 31, 2024, the Company receives net proceeds from one or more equity financings that the Board or the Compensation Committee, in their reasonable good faith judgment, determine are sufficient to provide the Company with working capital to fund its operations through the end of fiscal year 2025 (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Qualified Financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then Executive will be granted an additional stock option to purchase 340,000 shares of the Company&#x2019;s common stock (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financing Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Financing Option will be granted on or about the first trading day in an open window under the Company&#x2019;s insider trading policy following the date of the Qualified Financing and with an exercise price per share equal to the per share fair market value of the Company&#x2019;s common stock on the date of grant. The Financing Option will be granted pursuant to the Plan and will vest according to the same vesting schedule as the Initial Option. The Financing Option will be subject to the terms and conditions of the Plan and any form of stock option agreement issued thereunder.</font></div></div><p style="margin-left:6pt;text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08055555555555555in;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="x__expenses__the_company_will_reimburse_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive will be eligible to receive additional awards of stock options, restricted stock units or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board or the Committee will determine in its discretion whether Executive will be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">be in effect from time to time.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in the furtherance of or in connection with the performance of Executive&#x2019;s duties hereunder, in accordance with the Company&#x2019;s expense reimbursement policy as in effect from time to time.</font></div></div><div style="margin-left:0.5798611111111112in;display:flex;margin-top:9.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.112034876715629%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__severance_benefits__change_in_control"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severance Benefits; Change in Control Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__non_cic_qualified_termination__if_th"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-CIC Qualified Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. If the Company terminates Executive&#x2019;s employment with the Company outside of the Change in Control Period (as defined below) other than for Cause (as defined below), death or Disability (as defined in the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)), or Executive resigns from Executive&#x2019;s employment with the Company for Good Reason (as defined below) (such a termination, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Qualified </font><font id="xi__continued_payment_of_executive_s_ann"></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then, subject to Section 6, Executive will be entitled to the following:</font></div></div><div style="margin-left:0.3298611111111111in;text-indent:115.9pt;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.6097222222222223in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5865834797521225%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xii__reimbursement_by_the_company_for_th"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">continued payment of Executive&#x2019;s annual Base Salary, at the level in effect immediately prior to Executive&#x2019;s termination date, for a period of twelve (12) months following the date of the Qualified Termination, with the first payment paid on the first Company payroll date following the effective date of the Release (as defined below) (and to include any amounts that otherwise would have been paid between the termination date and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the payment date); and</font></div></div><div style="margin-left:0.3298611111111111in;text-indent:115.9pt;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.6097222222222223in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5865834797521225%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">reimbursement by the Company for the cost of premiums for Executive and Executive&#x2019;s covered dependents, if any, for group health insurance continuation </font></div></div><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.3298611111111111in;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.6097222222222223in;text-align:justify;"><div style="width:100%;display:inline;" id="xb__cic_qualified_termination__upon_a_qu"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">coverage under Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for up to twelve (12) months following Executive&#x2019;s termination of employment (the &#x201c;COBRA Premium Reimbursement&#x201d;), provided that (x) Executive and Executive&#x2019;s covered dependents timely elect and remain eligible for continued coverage under COBRA and (y) such COBRA Premium Reimbursement does not result in excise tax penalties for the Company under applicable laws (including, without limitation, Section 2716 of the Public Health Service Act). Notwithstanding the preceding, if the Company determines in its sole discretion that it cannot provide COBRA reimbursement benefits without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will instead provide the Executive a taxable payment in an amount equal to the monthly COBRA premium that the Executive would be required to pay to continue the Executive&#x2019;s group health coverage in effect on the date of termination of employment (which amount will be based on the premium for the first month of COBRA coverage), which payments will be made regardless of whether the Executive elects COBRA continuation coverage and will commence in the month following the month of the termination date and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">continue for the period of months indicated in this section.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CIC Qualified Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Upon a Qualified Termination occurring during the period beginning three (3) months prior to a Change in Control (as defined in the Plan) and ending twelve (12) months following a Change in Control (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) Period, then, subject to Section 7, Executive will be entitled to the following:</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:118.8pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.65in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:0.9500562879417551%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__a_lump_sum_payment_equal_to_twelve__"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a lump sum payment equal to twelve (12) months of Executive&#x2019;s annual Base Salary, at the level in effect immediately prior to Executive&#x2019;s termination date, paid on the first Company payroll date following the effective date of the Release;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:115.9pt;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.6097222222222223in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5865834797521225%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__a_lump_sum_payment_equal_to_hundred"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a lump sum payment equal to hundred percent (100%) of Executive&#x2019;s target bonus for the year in such the Qualified Termination occurred, paid on the </font><font id="xiii__cobra_premium_reimbursement_for_up"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">first Company payroll date following the effective date of the Release;</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:112.3pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.376718886445653%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiv__one_hundred_percent__100___of_the_u"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COBRA Premium Reimbursement for up to twelve (12) months following Executive&#x2019;s termination of employment, provided that (x) Executive and Executive&#x2019;s covered dependents timely elect and remain eligible for continued coverage under COBRA and (y) such COBRA Premium Reimbursement does not result in excise tax penalties for the Company under applicable laws (including, without limitation, Section 2716 of the Public Health Service Act). Notwithstanding the preceding, if the Company determines in its sole discretion that it cannot provide COBRA reimbursement benefits without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will instead provide the Executive a taxable payment in an amount equal to the monthly COBRA premium that the Executive would be required to pay to continue the Executive&#x2019;s group health coverage in effect on the date of termination of employment (which amount will be based on the premium for the first month of COBRA coverage), which payments will be made regardless of whether the Executive elects COBRA continuation coverage and will commence in the month following the month of the termination date and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">continue for the period of months indicated in this section; and</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:113.05pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5701388888888888in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.2115374498932105%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">one hundred percent (100%) of the unvested portion of any stock options or other equity award held by Executive that remain outstanding as of immediately </font></div></div><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.3298611111111111in;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5701388888888888in;text-align:justify;"><div style="width:100%;display:inline;" id="xc__non_duplication_of_payment_or_benefi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">prior to the date of such Qualified Termination shall immediately vest and become exercisable (but, in no case, will more than 100% of the shares subject to any award vest and become exercisable); provided, however, that any stock options or other equity award held by Executive that, at any time such equity award is outstanding, is subject to performance-based vesting, will vest assuming target performance. For purposes of clarity, any stock options or other equity award held by Executive as of any Qualified Termination not within the Change in Control Period will remain outstanding for three (3) months following such Qualified </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination in order to give effect to this provision.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Duplication of Payment or Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of clarity, in the event of that a Change in Control occurs within three (3) months following a Qualified Termination, any severance payments and benefits to be provided to the Executive under Section 5(b) will be reduced by any amounts that already were provided to the Executive under Section 5(a).</font></div></div><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Upon a Change in Control (as defined in the Stock Plan), then 50% of the unvested portion of any stock options or other equity award held by Executive that remain outstanding as of immediately prior to such Change in Control shall immediately vest and become exercisable.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__termination_for_cause__death_or_disa"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination for Cause, Death or Disability; Voluntary Resignation without</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. If Executive&#x2019;s employment with the Company terminates voluntarily by Executive for any reason (except upon resignation for Good Reason), for Cause by the Company or due to Executive&#x2019;s death or disability, then (i) all vesting will terminate immediately with respect to Executive&#x2019;s outstanding equity awards, (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and (iii) Executive will only be eligible for severance benefits in accordance with the Company&#x2019;s established policies, if any, as then in effect and subject to any conditions set forth by the Company as to the receipt of such severance benefits.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.5798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.112034876715629%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__conditions_to_receipt_of_payments__no"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Conditions to Receipt of Payments; No Duty to Mitigate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__separation_agreement_and_release_of_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Separation Agreement and Release of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The receipt of any payments or benefits pursuant to Section 5 will be subject to Executive signing and not revoking a separation agreement and release of claims in a form reasonably satisfactory to the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and provided that such Release becomes effective and irrevocable no later than sixty (60) days following the termination date (such deadline, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Release Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under this Agreement. In no event will severance payments or benefits be paid or provided until the Release becomes effective and irrevocable.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:1.3298611111111112in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.6906237504998005%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__limitation_on_payments_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limitation on Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.8258924504812704%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that the payments and benefits provided for in this Agreement or other payments and benefits payable or provided to Executive (i) constitute &#x201c;parachute payments&#x201d; within the meaning of Section 280G of the Code and (ii) but for this Section 6(b), would be subject to the excise tax imposed by Section 4999 of the Code, then your payments and benefits under this Agreement or other payments or benefits (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">280G Amounts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will be either:</font></div></div><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:1.590277777777778in;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.22986111111111113in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533511993904522%;display:inline-flex;justify-content:flex-start;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">delivered in full, or</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:1.0798611111111112in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.1531043372401117%;text-indent:0;display:inline-flex;justify-content:flex-start;">(y)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">delivered as to such lesser extent which would result in no portion of such payments and benefits being subject to the excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code, results in your receipt on an after-tax basis, of the greatest amount of 280G Amounts, notwithstanding that all or some portion of the 280G Amounts may be taxable under Section 4999 of the Code.</font></div></div><div style="margin-left:0.0798611111111111in;text-indent:108pt;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.8258924504812704%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reduction Order</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In the event that a reduction of 280G Amounts is being made in accordance with this Section 6(b), the reduction will occur, with respect to the 280G Amounts considered parachute payments within the meaning of Section 280G of the Code, in the following order:</font></div></div><div style="margin-left:1.0798611111111112in;text-indent:72pt;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.3791802926503225%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">reduction of cash payments in reverse chronological order (that is, the cash payment owed on the latest date following the occurrence of the event triggering the excise tax will be the first cash payment to be reduced);</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:1.0798611111111112in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.3791802926503225%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancellation of equity awards that were granted &#x201c;contingent on a change in ownership or control&#x201d; within the meaning of Code Section 280G in the reverse order of date of grant of the awards (that is, the most recently granted equity awards will be cancelled first);</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:1.0798611111111112in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.3791802926503225%;text-indent:0;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">reduction of the accelerated vesting of equity awards in the reverse order of date of grant of the awards (that is, the vesting of the most recently granted equity awards will be cancelled first); and</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:1.0798611111111112in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.3791802926503225%;text-indent:0;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">reduction of employee benefits in reverse chronological order (that is, the benefit owed on the latest date following the occurrence of the event triggering the excise tax will be the first benefit to be reduced).</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.058333333333333334in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In no event will Executive have any discretion with respect to the ordering of payments or benefits.</font></p><div style="margin-left:0.0798611111111111in;text-indent:108pt;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.8258924504812704%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Unless the Company and Executive otherwise agree in writing, any determination required under this Section 6(b) will be made in writing by a nationally recognized accounting or valuation firm (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) selected by the Company, whose determination will be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required by this Section 6(b), the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section 6(b). The Company will bear all costs and make all payments for the Firm&#x2019;s services relating to any calculations contemplated by this Section 6(b).</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:1.3298611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.6906237504998005%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__section_409a_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.0798611111111111in;text-indent:114.5pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5902777777777777in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.620388457606704%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__notwithstanding_anything_to_the_cont"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A of the Code, and the final regulations and any guidance promulgated thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Deferred Compensation Separation Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will be paid or otherwise provided until Executive has a &#x201c;separation from service&#x201d; within the meaning of Section 409A.</font></div></div><p style="margin-left:48.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:111.6pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5499999999999998in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.0657786864505419%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any severance payments or benefits under this Agreement that would be considered Deferred Compensation Severance Benefits will be paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following Executive&#x2019;s separation from service. Any installment payments that would have been made to Executive during the sixty (60) day period immediately following Executive&#x2019;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive&#x2019;s separation from service and the remaining payments shall be made as provided in this Agreement.</font></div></div><p style="margin-left:48.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.8258924504812704%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement, if Executive is a &#x201c;specified employee&#x201d; within the meaning of Section 409A at the time of Executive&#x2019;s termination (other than due to death), then the Deferred Compensation Separation Benefits that are payable within the first six (6) months following Executive&#x2019;s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#x2019;s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive&#x2019;s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#x2019;s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div></div><p style="margin-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:108.7pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5097222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.6781206667948703%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any amount paid under this Agreement that satisfies the requirements of the &#x201c;short-term deferral&#x201d; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for purposes of clause (i) above.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:111.6pt;font-size:0;margin-top:4.5pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5499999999999998in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.0657786864505419%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit (as defined below) will not constitute Deferred Compensation Separation Benefits for purposes of clause (i) above.</font></div></div><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:6pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.058333333333333334in;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:108.7pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1.5097222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.6781206667948703%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;" id="xvi__the_foregoing_provisions_are_intend"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A. In no event will the Company have any liability or obligation to reimburse, indemnify, or hold harmless Executive (or any other person) for any taxes or costs that may be imposed on or incurred by Executive (or any other person) as a result of Section 409A.</font></div></div><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__confidential_information_agreement__"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Executive&#x2019;s receipt of any payments or benefits under Section 5 will be subject to Executive continuing to comply with the terms </font><font id="xe__no_duty_to_mitigate__executive_will_"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of Confidential Information Agreement (as defined in Section 8).</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Duty to Mitigate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will any earnings that Executive may receive from any other source reduce any such payment.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.5798611111111112in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.112034876715629%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__definitions_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__cause__for_purposes_of_this_agreemen"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cause. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is defined as (i) an act of material dishonesty made by Executive in connection with Executive&#x2019;s responsibilities as an employee, (ii) Executive&#x2019;s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude, (iii) Executive&#x2019;s gross misconduct, (iv) Executive&#x2019;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Executive owes an obligation of nondisclosure as a result of Executive&#x2019;s relationship with the Company; (v) Executive&#x2019;s willful breach of any obligations under any written agreement or covenant with the Company; or (vi) Executive&#x2019;s continued failure to perform Executive&#x2019;s employment duties after Executive has received a written demand of performance from the Company which specifically sets forth the factual basis for the Company&#x2019;s belief that Executive has not substantially performed Executive&#x2019;s duties and has failed to cure such non-performance to the Company&#x2019;s satisfaction within 10 business days after receiving such notice.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__good_reason__for_purposes_of_this_ag"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Executive&#x2019;s resignation within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without Executive&#x2019;s consent: (i) the assignment to Executive of any duties, or the reduction of Executive&#x2019;s duties, either of which results in a material diminution of Executive&#x2019;s authority, duties, or responsibilities with the Company in effect immediately prior to such assignment, or the removal of Executive from such position and responsibilities; provided, however, that a reduction in duties, position or responsibilities solely by virtue of the Company being acquired and made part of a larger entity, whether as a subsidiary, business unit or otherwise (as, for example, when the Chief Executive Officer of the Company remains the Chief Executive Officer of the Company following a Change in Control where the Company </font></div></div><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.3298611111111111in;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">becomes a wholly owned subsidiary of the acquiror, but is not made the Chief Executive Officer of the acquiring corporation) will not constitute &#x201c;Good Reason;&#x201d; (ii) a material reduction of Executive&#x2019;s Base Salary (in other words, a reduction of more than 10% of Executive&#x2019;s Base Salary in any one year); (iii) a material change in the geographic location at which Executive must perform services other than as contemplated by Section 1(d) (in other words, the relocation of Executive to a facility that is more than fifty (50) miles from the location Executive must initially perform services); and (iv) the failure of the Company to obtain assumption of this Agreement by any acquirer or successor. Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#x201c;Good Reason&#x201d; within ninety (90) days of the initial existence of the grounds for &#x201c;Good Reason&#x201d; and a reasonable cure period of not less than thirty (30) days following the date of such notice.</font></div></div><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__section_409a_limit__for_purposes_of_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A Limit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A Limit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; will mean the lesser of two (2) times: (i) Executive&#x2019;s annualized compensation based upon the annual rate of pay paid to Executive during the Company&#x2019;s taxable year preceding the Company&#x2019;s taxable year of Executive&#x2019;s termination of employment as determined under Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Executive&#x2019;s </font><font id="x__confidential_information__executive_a"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">employment is terminated.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Executive agrees to abide by the terms of the Confidential Information, Invention Assignment and Arbitration Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) entered into on or about the Effective Date.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__cooperation__the_parties_agree_that_c"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The parties agree that certain matters in which the Executive will be involved during the Employment Term may necessitate the Executive&#x2019;s cooperation in the future. Accordingly, following the termination of the Executive&#x2019;s employment for any reason, to the extent reasonably requested by the Company, the Executive shall cooperate with the Company in connection with matters arising out of the Executive&#x2019;s service to the Company; provided that, the Company shall make reasonable efforts to minimize disruption of the Executive&#x2019;s other activities. The Company shall reimburse the Executive for reasonable expenses incurred in connection with </font><font id="x0__representation_of_the_executive__the"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">such cooperation and, to the extent that Executive is required to spend substantial time on such matters, the Company shall compensate Executive at an hourly rate based on the Executive's Base Salary at the time of termination of the Executive&#x2019;s employment.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Representation of the Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Executive represents and warrants to the Company that:</font></div></div><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__the_executive_is_not__as_of_the_effe"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Executive is not, as of the Effective Date, currently employed or engaged as an independent contractor with any other entity, and Executive&#x2019;s acceptance of employment with the Company and the performance of his duties hereunder will not conflict with or result in a violation of, a breach of, or a default under any contract, agreement or understanding to which he is a party or is otherwise bound.</font></div></div><div style="margin-left:0.3298611111111111in;text-indent:72pt;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.847633276168632%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__the_executive_s_acceptance_of_employ"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Executive&#x2019;s acceptance of employment with the Company and the performance of his duties hereunder will not violate any non-solicitation, non-competition or </font><font id="x1__assignment__this_agreement_will_be_b"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">other similar covenant or agreement of a prior employer.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;" id="x2__notices__all_notices__requests__dema"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of Executive upon Executive&#x2019;s death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">successor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or other disposition of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive&#x2019;s right to compensation or other benefits will be null and void.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:6pt;text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08055555555555555in;text-align:justify;" id="if_to_the_company_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All notices, requests, demands and other communications called for hereunder will be in writing and will be deemed given (i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight service, or (iii) four (4) </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as the parties may later designate in writing:</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:78pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:</font></p><p style="margin-left:78pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="viracta_therapeutics__inc_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Viracta Therapeutics, Inc.</font></p><p style="margin-left:78pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="x533_south_coast_highway_101__suite_210"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2533 South Coast Highway 101, Suite 210</font></p><p style="margin-left:78pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cardiff, CA 92007</font></p><p style="margin-left:78pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="attn__chief_executive_officer"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attn</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:78pt;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="if_to_executive_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If to Executive:</font></p><p style="margin-left:78pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="at_the_last_residential_address_known_by"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">at the last residential address known by the Company.</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;" id="x3___severability__in_the_event_that_any"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision. The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Agreement or by making such other modifications as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="x4__arbitration__executive_agrees_that_a"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Arbitration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Executive agrees that any and all controversies, claims, or disputes with anyone (including the Company and any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive&#x2019;s service to the Company, will be subject to arbitration in accordance with the provisions of the Confidential Information Agreement.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;" id="x5__integration__this_agreement__togethe"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Integration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement, together with the Confidential Information Agreement, the Company&#x2019;s equity incentive plans and the other equity documents referred to herein, represents the entire agreement and understanding between the parties as to the subject matter herein and </font></div></div><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.0798611111111111in;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">supersedes all prior or contemporaneous agreements whether written or oral. This Agreement may be modified only by agreement of the parties by a written instrument executed by the parties that is designated as an amendment to this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;" id="x6__modification__waiver_of_breach__no_p"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Modification: Waiver of Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and by the Board or its designee. The waiver of a breach of any term or provision of this Agreement, which must be in writing, will not operate as or be construed to be a waiver of any other previous or subsequent breach of this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;" id="x7__headings__all_captions_and_section_h"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this Agreement.</font></div></div><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;" id="x8__tax_withholding__all_payments_made_p"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;" id="x9__governing_law__this_agreement_will_b"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement will be governed by the laws of the State of California </font><font id="x0__acknowledgment__executive_acknowledg"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(with the exception of its conflict of laws provisions).</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;" id="x1__counterparts__this_agreement_may_be_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Acknowledgment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain advice from Executive&#x2019;s private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">knowingly and voluntarily entering into this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.5222517990708595%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement may be executed in counterparts, and each counterpart will have the same force and effect as an original and will constitute an effective, binding agreement on the part of each of the undersigned.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:130.65pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.8145833333333334in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Remainder of Page Intentionally Left Blank</font></p><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"><div class="page" style="flex-direction:column;display:flex;min-height:11in;"><div style="margin-left:-0.92in;position:relative;"><div style="transform:translate(0px, 0px) rotate(0.0deg);z-index:-1;overflow:hidden;top:10.3in;left:4.13in;width:0.2638888888888889in;position:absolute;height:0.21250000000000002in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.4in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:6pt;text-indent:36pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.058333333333333334in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, each of the parties has executed this Agreement (in the case of the Company, by a duly authorized officer or director), effective as of the Effective Date.</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:6pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COMPANY:</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:6pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">VIRACTA THERAPEUTICS, INC.</font></p><p style="margin-left:6pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:6pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:6pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Mark Rothera				</font></p><p style="margin-left:6pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:6pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By:	Mark Rothera</font></p><p style="margin-left:6pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title:	President &amp; Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE:</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Michael E. Faerm				</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Michael E. Faerm</font></p><div style="flex-grow:1;"></div><div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></div></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>virx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">San Diego, May 14, 2024 &#x2013; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We are delighted to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">welcome Mike, an accomplished life sciences industry &amp; Wall Street veteran who we believe will be instrumental in supporting our next phase of development,&#x201d; said Mark Rothera, President and Chief Executive Officer of Viracta. &#x201c;The encouraging clinical data generated to date underscores the potential of Nana-val&#x2019;s innovative </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2018;Kick and Kill&#x2019;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> approach to effectively address the unmet treatment needs for patients with EBV-associated cancers. As we advance Nana-val through late-stage development and towards several pivotal milestones, we look forward to leveraging Mike&#x2019;s strategic, operational and financial leadership.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Mr.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Faerm added, &#x201c;I am thrilled to join Viracta at this exciting time and relish the opportunity to make a meaningful impact on the company&#x2019;s future. I look forward to working with the talented team at Viracta to progress the development of Nana-val and advance the company&#x2019;s mission to bring innovative therapies to patients with virus-associated cancers.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Mr. Faerm most recently served as Interim Chief Financial Officer at Harpoon Therapeutics, Inc., which was acquired by Merck for approximately $680 million, and where he helped lead a $150 million PIPE financing. Prior to Harpoon, Mr. Faerm was the Chief Financial Officer of Artiva Biotherapeutics, Inc., where he led financial strategy and operations, and oversaw the company&#x2019;s investor relations, financial planning, accounting and facilities functions. Previously, Mr. Faerm served as a consulting and interim Chief Financial Officer and Chief Business Officer for numerous biopharma companies. Prior to this, Mr. Faerm served as the Chief Business Officer of Innoviva, Inc. (formerly Theravance, Inc.), and earlier, worked in business development and strategic finance roles at Forest Laboratories and Regeneron Pharmaceuticals. Mr. Faerm&#x2019;s Wall Street experience includes Credit Suisse and Wells Fargo Securities, where he was a senior equity research analyst covering the pharmaceutical sector, and Merrill Lynch, where he was an investment banker executing a wide range of strategic and capital markets transactions in biopharma and other healthcare sectors. Mr. Faerm earned his MBA from Harvard Business School, an M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from Columbia University.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta&#x2019;s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> nasopharyngeal carcinoma (NPC) and other advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> solid tumors. Viracta is also pursuing the application of its &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Kick and Kill</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; approach in other EBV-related diseases.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For additional information, please visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.viracta.com</font></font><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This communication contains &#34;forward-looking&#34; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the ability of Viracta&#x2019;s product candidates to effectively address the unmet treatment needs for patients with EBV-associated cancers, the details, timeline and expected progress for Viracta's ongoing and anticipated clinical trials and updates regarding the same, the announced changes to management, statements concerning or implying Viracta&#x2019;s future performance, goals and potential, and the ability of management personnel to contribute to the execution of Viracta&#x2019;s vision, performance, goals and potential. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta's ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta's plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta's planned clinical trials; the timing of the availability of data from Viracta's clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta's plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits, and market acceptance of Viracta's product candidates; Viracta's ability to manufacture or supply nanatinostat, valganciclovir, and pembrolizumab for clinical testing; and Viracta's estimates regarding its ability to fund ongoing operations into 2025, future expenses, capital requirements, and need for additional financing in the future.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#34;Risk Factors&#34; and elsewhere in Viracta's reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.sec.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investor Relations Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Ashleigh Barreto</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Head of Investor Relations &amp; Corporate Communications</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">abarreto@viracta.com</font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></font><font style=""></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SOURCE Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>virx-20240511.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-14T16:33:08.4802+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://viracta.com/20240511" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:virx="http://viracta.com/20240511" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="virx-20240511.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140442075611568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 11, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 11,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Viracta Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001061027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3295878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2533 S. Coast Hwy. 101, Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cardiff<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-8470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,  par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 4H2N6#JJHN=  0  / (
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M7>EYIM<WDUM)Z.#<@V#OX96,'<V/'W?W U!+ P04    " !2A*Y8)!Z;HJT
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M2P$"% ,4    " !2A*Y8!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %*$KEAA9B8>[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M %*$KEB97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ 4H2N6-WEU]YE!   JQ   !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M %*$KEB?H!OPL0(  .(,   -              "  :@,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ 4H2N6)>*NQS     $P(   L              ( !
MA \  %]R96QS+RYR96QS4$L! A0#%     @ 4H2N6#JJHN=  0  / (   \
M             ( !;1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %*$
MKE@D'INBK0   /@!   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %*$KEAED'F2&0$  ,\#   3
M          "  ;\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(   D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="virx-20240511.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  virx-20240511.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="virx-20240511.htm">virx-20240511.htm</File>
    <File>virx-20240511.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "virx-20240511.htm": {
   "nsprefix": "virx",
   "nsuri": "http://viracta.com/20240511",
   "dts": {
    "inline": {
     "local": [
      "virx-20240511.htm"
     ]
    },
    "schema": {
     "local": [
      "virx-20240511.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_07c6a872-44b2-4f1f-8947-e6528df029da",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "virx-20240511.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07c6a872-44b2-4f1f-8947-e6528df029da",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "virx-20240511.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://viracta.com/20240511/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-24-059668-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-059668-xbrl.zip
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M'T#R)&RYC-=D@@XXYHQAFH#LEK\9A8""I1EA5YCY$_(U"_;Z4X9RL='K^E9
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MWE]\[<(FU50UEKW"B-UH 1=J,C ;G8_B@_*:&7Q[,'?OQ+_R-./AI!Q%MM*
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M>$'"9(Z!W<A4>$9O"@S+[FW7=5=V+]-!,=BN1?%;M?;!N+1W80Y-&DF>2D<
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MX"+D#2+K!Y8+EM="-PB+-T^2D+,'C'VETP936O,"C*(4!N( NO&A5,)7NKJ
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M\60\&H^?;OSOJ*WT 06GK6+O^=/;BE,6Q,Y6^L S[&<K!6S:[8::<\P@X)
M# Q1?R211K\T7-42J;+@@HYNR\3>>ZJZ<*XOYQ.76./\6D9PA'9&XUV/<,C9
M@P)QGUW1;&4\!P;-*"DCNX+6-G> X6VDMJN?DQ:][7[XHXRD:%0'X$=<T(^Y
MRB0[79?(_:61"+9*CRY71\YFRO.F#DXE3(&,U_*30Y.@TYX@K&=J[YYCAWI9
M]G9DV6.%62N$<!4W68V\P.37!PF7RH0/+U6QS&JE2_"<-(B? ('9,O0L(8##
MQ(<-,.O?0HH(!(BE]/.TP.1SV*<X="W%X:!/<>A3'+X\-V"?XM!.BD-7E(Q'
M9LO?X7I$SBE?P&];,C<PTC#713F]SV@2>_\L(6XQG'X5$GO.+\M838O,^Z$(
MD6/GHX16 A4IOGG?!73ECTY/)IQ9CI4QX:V=#CIB+G[YX>.[#K@L2*UAZK<[
M+:M'5>"L>"=II-ZOK(?!DCG*F^,XJ1:LVX&K90MES590BZ0NJ09?%6B%NNQ4
MI7E;VWG<4WQMYW:7<3-W=+XL\)=*+$M.UNX-P3IS<0,6:PQ:(M5RK]%1\<<<
MG$TDKMVJV\W<U<:1-#X>'5GP8S&%-KR_L3[Z2:?<PC'8;:Y9N$(<%7]"51WH
M#L%8,\.9+6L8@-6?Y!; SA-44\E-85<SCE6"VXXKT%^I).(2?-49>.8):*BV
M@77WI @KV'MGD^&J,>Q)6[",$6;3O(K,I=,!8^'!:Q.CD2>+#/BI+'E<B5&=
M.,W--MS$K5BQ->Q.+5TJ-73O':>1:0CT0(SOD>L2ZD;,$,Q69>\'IWE#8SQ.
MTP=;%D-/5,ER1A4HFLG9JO-"!S2S[3K6DQVH!1MS3>7 0C:X5U4GC.UI!YTB
M=IW-Y):^+"UE06?&(LU.,>6,]WI?I:-'%_<9=X_5K+H8K_X?8G5M[I>7!(A0
MH]24DLA<2XFIA'T8\P]3"=K9@57.K!]=-(2M&^++&)O=)6&H2T[<J? U-MK1
MJ/.FJ'T7]&ONR1V1P>.G1P9[N%-SK.!D_Z0-Q-/^4;M0Q^'^Z60XG!R-3XY/
M#T?'D\FHM2BG[PL_*I8K/RN6%E- NC12]+$ \MO).!$>=@Q.Y-)J_*62ORX9
M6PR!/G]<\GQ;*?**$J0++)]]N+%;X<82.W&76%F /@FV=N>DBNY7R3^'8]S=
M(%FX!(8F4C>F(R7W@T@AW]1&@(-6*&58%1T-B"]%F*]I*GSM :AA4A"$4JS:
M)"1O6=Y]C5K3>/^@%:UI,JF(NW&KX@XF 1-%3DY.C@X/)T>3@^>0=EN*NRO?
M3V)IQ)JOQ8?OPSN^CPA-Q(VU$[NYRS_^ I&%/D[0QPGZ.$$?)^CC!)4XP4:8
MY<-4G*]0QSEPF M?5\DY'HY<I%/+2LX8+-R#X\/#TY/3@_%H^!PVW=4;@) B
M']QF:PP/7Q$CDQ'^NJR(1&P:+ME(,ZD(R.*HEFU.(E_K&)AQ9BY;0;+/]0SU
MZ-&NH4</>_1HCQ[]\OP#/7JT)8+L#N@6C_$^!)RX'A9DA!%>-)F5Z:&IIK1H
M13172D0: X?L\6:_:+80:-\YURTS&<9H>X']( TS(]EW.],B)Q*7&(PPL()T
MZ<ZRLC;.FM$7-.&G2X ;&WW@CH_LGEN/QL!;)-=(NC%@=>%IV@:%H2@U'MEB
MUKC"L.J,HX@,\-].WQVVFSTV #6OX\ E@,RR8DF6%;NJG9>X)N:J2$$*,PTJ
MW$@I?'WPA&$)RU'6O+KH;D"'@$FGWY3*KPF&UI0QMKMJ((O2?JSMJ_8,17?,
MRJGX.B>+F8U^.A-8LA4W5_8D*-F;O>%ZFI2W1%'9+1 9$I_\6%YY*'A^-;G0
M:1=8CS8+6"W^X";AQ&V^3!K$(44)LU)D;I1\&W!K6I9;GBCKYN.K3OMVN4AY
MZ;9/:BX^]G(;I^UD9[IKW81@G1<!$[>M)4F+"(R?\-:[ENEC6A>[CV-,>X*H
M>%EPP)<F+L(W+2[6#E<'L*8/PH1^(DV,D*&: G]2ZK1M^<"L6L^AM;5Q/$J-
M[Q6?7O%Y54DFMPKR2[^2DHG FP )Q7R?V,/0T(871<?DGFN*6 ZT@??C.N'9
MN?=;$L'UC74O/Q(;E[ $JR -VI.7VQIR+SJO#M]8RRQ[CR1+<XCXKO1ZPR>K
M%P$Q^E"]'N93DS=87\C#)&1-U%9N*&<B=@<.S5Z-]0-^'A9R Z#6TN^%=C?J
MNVY'[7I"NS/P*B+%TPZA<L/4"[(V?,>]U"J\[ ,/D8[T):LCH\;N%ABJ#<C]
M0DDI?%<'S30*4KF-KFS49"E2N/5WN;@L(9'J20=)C.LDJQ"84KFW^OR#28UA
M+J:1RA:D/T18^L@A4^&J(+$#4ZB7%H=)<*I]9)+P1/"QVD3Q</$G5"-@E5L7
MX'K?>U5 ;4,%?>?5_S720!]M20-=[F=$*>O]ZGC3,W2U=^R&ORC/()RSC^49
MT^Z0[-S[D'@_%CG)K)_AT3G(HYX.N@MGO%?WNTP'G<F5X!/KVQ)5/MR"(!@(
MLXZ"H6/"X)/MLO?.5M7"B]O0'2(&,!)JV7HQ"4<9T'D#6NU*2TW&+?UC/81-
M-<A*30F54U/,C1&]5\GO["(ME].I.,;08CLW <T-J5!<J\R6L[CU4 _,9B+(
MD_36J#1&R>EJWJU>]BZDV>),5['AI 2:C<E^H<S)$L$75(H+R-#B./$0G:()
MO3-U@R3=1\-=+!=8IQA=0XXR 308&B$>-<84=W>]T#ZGCG9@X2R5N^F;1<L;
M5YY=,:WYUP>QECX-)VLF%4>_Z4XBU:4T!UP98*H^JJR4:- EBOES!(6:; AR
MN*U@@(,2K=)R#X+YI:)*A^_=@[WN8G2745UWN=,^N9?=X^T9*4>GPZ/QP?%D
M>'AZ>C)$7.[+TWA8IK@RF\*'_[/&2<>4D;_;7F)V@C%'>LNC_=-[;^&YT; =
M7H:V*\^=C"<GI^-#.-4GH_'Q\/#U:1G:.!CO74""37YJ1@O8ZW/&I=BJ-W,9
M:]SPMK@E7<Z]AROZ.SI\H6,PHWF1ERH::N[! G]BVC7ZB0LH6TI!RC\H\C;'
M[&3XUY*H,I3&O;KK38M< \I@ +8(!,CD09GL52MS["0%JB7B.BB :MZ%B^#4
M_91V8=\FQ:;9:-)M&F;0562Z:FC0/+]CGW8'E-:2ID?A7-Y7K:-/VGCUI9KT
M21M]TL:7IW#U21O/E[0!ZN#I<'QL_YS<86+>B^5[O(59\\VW2^X#XSLXF(Q&
MIZ<'I\/#R7B\C;UY\P9TT1!6AMD@0*F;%5&$A>)ZP\T>B>%Z6/BKKQ@^WA]-
M#D;#PX.#X_'A$'IW_'2[[?9-G14&69"/&_D:J+IV3LY1XG=@@Z9D-XD3%S%*
MKS5;*%/)B36;S* J>GO= J+/HVO6_!B4%CE/*"##Q@)828("-"I&4$D0$+<%
M/NJPBLPD?$: *,AR0P,1)8% )A!R04-7)/=\&S.-YX6B/F2LV= 4TX:@(KB'
MC<&UH:"_^ETPV!!%E1LZ#OBQ:P0-T$5>XVTA5'R$]ER&O7:6 !MTW_:6@K ^
MALGD[GE^'&+^*:Z?PY=DT_L"G3\O[OUY40?N1TSOH!WW"^JCK0(=UUQ4@K-/
MS FJG!YE)!?QV#0"XM:</HQ0,RTRX@[S;P9KR,*UPXH.*Q62(%YW5#W20673
M@\J )AD#CRDX>J^6\-5FQ1P<GXY.AN/3\=%D>/ L#)FC-Z G5 Y*(#+GME>(
MZ(7[&>[+8)$F,?1GKO!FY:35'28+R_AXN*]ZR77).A7Q3=A ^JB)+BFJ.W./
M,&R7N;1<ZLZ5;3QW)7M5Y;.<K:83SW9[VLAG.?-?+)CL^<_[^ V<]P ONB@J
M*>1<K#O?GI25.4]%C-EC)I[ !&=S.MV(@ IL8E=R'8.,6*B5IVD7TR2Z)P)#
MT9;*+:>?,?*&)0P\:7@AJ#M&3.C.5@70$FN&HGH>Y]&M[7YU>$9^Z$G 2!5*
MD5Y4]*+BE47%P1L0%175@,Y= *<&C.V\I!19%R%//\E.TT\^V$_C5NP/=W^X
MMSC<AV_M<'-2H*PFBCU<]]=OO:+:;[Y8U?BW!G&]S5/>&#V=[)]6N5&?-MCZ
M09Z<'%3^'%8/;WN8@374KY.!*0BM>^L273?Y;6AKZXNG"6"S_^+HN1<N2?(E
M.E'?MA?U)Y4N6V4;B8G"NY*3Z_+P,]SL&@4QY<7@O7"=*B:3<RGEV9ZT!.@.
M>LWUI%8YQ,NVB"3(XT:(/Q[4O60>P^!"$_9A9Z=W)2+-(0X7P;*SD+=VU[6$
MNF7$P<Y!+F>1,?B68+I&9?6L$IT@1W]F<ARFBF-4E.)_FQ0VEF9V#%$"8'J\
M)K1:I[=:<AB/_8114+#[(2OW"W6OT>V.,TD1+VA#EBE7D@D,-8L-]DBL5FER
MHY:Z:1R$3.-:"8(R&(A-IIAZ3]O6M#KPYLA9,!-X/2B8SQ36)5]OTHE!&AU*
M=SUC?P9^8BT41\EMS>>,<U\*:#U;F/N(ADX!6!43-R/GI\%[81(4.B*;56?)
MR4G#R445S&49I$D4M77?<%BKW=6;0_!2!V"3F7G$%EUR!,. CWTJ&04R+MN
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MNC4]DF$CP%@/,P[I;9PF'0# V2(='G;(GCLJ[9!?ZQ-C_$0I"D XC(;>M,A
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MMU=JMD_3K?IV_.!029,DKVUY8@UF)CK.SDR75.+$Q6::,G0N(+"V#36XD.U
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M<1-*]+Y3'_OWZ3<E/?YJ_S[_CJ7_ 5!+ 0(4 Q0    ( %.$KEAQ2CO"GA\
M $?F   1              "  0    !V:7)X+3(P,C0P-3$Q+FAT;5!+ 0(4
M Q0    ( %.$KEA8'R3D8@@  #5=   1              "  <T?  !V:7)X
M+3(P,C0P-3$Q+GAS9%!+ 0(4 Q0    ( %.$KEAZ1(:C]SH  +\0 @ /
M          "  5XH  !V:7)X+65X,3!?,2YH=&U02P$"% ,4    " !3A*Y8
M53] V_4-  !J20  #P              @ &"8P  =FER>"UE>#DY7S$N:'1M
64$L%!@     $  0 ^    *1Q      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>virx-20240511_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="virx-20240511.xsd" xlink:type="simple"/>
    <context id="C_07c6a872-44b2-4f1f-8947-e6528df029da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001061027</identifier>
        </entity>
        <period>
            <startDate>2024-05-11</startDate>
            <endDate>2024-05-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_b7edf96c-794a-42a4-84dd-2c7fedebb45b">0001061027</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_267b1bc7-c8c7-4182-993a-ae035f4151c7">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_3bbcc399-9f38-4064-a2ad-82842024fb72">Viracta Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_56dac0f8-c68b-4d0a-b43d-2cc3654709f4">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_7c3dad9d-83d8-4777-a997-d82e8ec539ba">2024-05-11</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_999ddabf-d760-42f6-853e-964c2998b0c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_f52fc544-3724-4e39-b4da-9ddadf28e5ca">000-51531</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_82a76906-381e-44f6-b5a6-a18d73d0d98a">94-3295878</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_d32c7eed-e02d-4c06-a0b4-c229cf36794a">2533 S. Coast Hwy. 101, Suite 210</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_38149988-987f-45a4-923c-3ae7a06214c8">Cardiff</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_12f6da04-b136-4be5-94f3-1845c8df1159">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_44ca4d6e-b5d1-45e4-bb7b-1116417169c7">92007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_fbdf5322-9b69-4d88-8455-5a6dd7236432">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_e105fc6c-3f75-4e56-b96e-03c2fd159cab">400-8470</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_976b2a25-fb6c-450d-b313-06b3a1953286">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_faa07df1-dca3-49b9-a2ba-646d59860885">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_fd3125fe-6add-4a99-8f14-ebb810133a23">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_ee7bb1dc-56cd-4cb5-8801-def081590c9b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_5fbc1138-b951-46c7-a0ab-bca915b4be4b">Common Stock,  par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_dd9a21b9-3718-4fa5-9193-0154a4800fcb">VIRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_e84909f1-1aec-49c5-bb0b-26c015cfc4db">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_07c6a872-44b2-4f1f-8947-e6528df029da"
      id="F_55d3573e-4ef3-4d5a-9692-2298c70bc72a">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
